Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | MLYCD | O95822 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CASR | P41180 | 1/20 | 0.34 |
| ▸ | CCKBR | P32239 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19543467 | 0.82 | SIGMAR1 (0.46) | EPHX1SIGMAR1MLYCDSMN1; SMN2KDM4C | |
| SCHEMBL2625567 | 0.78 | EPHX1 (0.47) | EPHX1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL20953587 | 0.78 | EPHX1 (0.80) | EPHX1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20017286 | 0.78 | EPHX1 (0.52) | EPHX1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL19703763 | 0.76 | FAAH (0.49) | EPHX1ALDH1A1SIGMAR1MEN1KMT2A | |
| SCHEMBL19303878 | 0.76 | SIGMAR1 (0.42) | EPHX1SIGMAR1MLYCDKDM4C | |
| SCHEMBL4577394 | 0.76 | EPHX1 (0.59) | EPHX1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL13617058 | 0.76 | SIGMAR1 (0.42) | EPHX1SIGMAR1MLYCDKMT2AKDM4C | |
| SCHEMBL4577399 | 0.76 | EPHX1 (0.59) | EPHX1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL2625542 | 0.76 | EPHX1 (0.70) | EPHX1ALDH1A1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938323-B2 | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase | NOVARTIS AG (CH) | 2018-04-10 | — | — | US | disclosed |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | EPHX1 4394/4885ALDH1A1 3212/4885SIGMAR1 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.